Navigation Links
Array BioPharma and Amgen Partner in Type 2 Diabetes
Date:12/14/2009

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our potential to earn future milestone and royalty payments under our agreement with Amgen, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate and future plans to progress and develop ARRY-403. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidat
'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
2. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
3. Worlds most complex silicon phased-array chip developed at UC-San Diego
4. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
5. New Microbial Genome-to-Array Service
6. Jivan Awarded US Patent #7,340,349 for Splice Array Analysis
7. Immucor To Acquire BioArray Solutions Ltd.
8. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
9. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
10. Array BioPharma Selects SciQuest to Automate Procurement and Enable Agile Drug Development
11. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  US-Australian drug discovery company, Novogen Limited ... its comprehensive scientific review has identified high value ... of unmet patient need. Novogen is moving as ... prior to entering into Phase 1 clinical trials ... Chief Executive Officer, Iain Ross , said ...
(Date:8/31/2015)... FRANCISCO, Calif. , Aug. 31, 2015 ... discovery and development of novel cancer immunotherapies, announced today ... Ph.D., as Chief Executive Officer and William Ho ... and Ho join an experienced management team led by ... Jordan Fridman , Ph.D., Chief Scientific Officer; Jay ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
(Date:8/31/2015)... ... 2015 , ... The Food Processing Suppliers Association's PROCESS EXPO ... manufacturers and leaders in the field of academia. , METTLER TOLEDO will ... of bakery and snacks; beverages; dairy; meat, poultry and seafood; and prepared foods. ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... we just escaped January a notoriously depressing month ... and dank weather thats no surprise. In fact, ... week ago) was the most depressing day of the ... psychological burden because of the challenges they face, their ...
... for presentation times at the Midwest Venture Summit on May ... will be selecting only a handful of presenters out ... , ,Applicants will be reviewed by a panel of investors ... consider the products that each company is producing and developing, ...
... W.M. Keck Foundation of Los Angeles has given ... how stem-cell cultures remain able to develop any other type ... scientist James Thomson was the first to grow ... are given some impetus to form other kinds of cells ...
Cached Biology Technology:Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4Follow the money 2Follow the money 3
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... Global Rainmakers, Inc., an intellectual property holding company ... has exited its "stealth" mode and is prepared to ... cutting-edge biometric security offerings. , During the past four ... dollars to develop and deploy a series of core--but ...
... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
... discovered the pivotal role that volcanoes played in a ... ironically, these volcanoes first caused global warming -- by ... When they stopped erupting, Earth,s climate was thrown ... discovery underscores the importance of carbon in Earth,s climate ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Volcanoes played pivotal role in ancient ice age, mass extinction 2Volcanoes played pivotal role in ancient ice age, mass extinction 3
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
RABBIT ANTI PARATHION...
Recombinant Rhesus Monkey IFN-Alpha...
Biology Products: